RVRay Valencia

Ray Valencia

*This is an algorithmically generated author record based on publicly available information.

Ray Valencia has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Calibration of Uncertainty in Sea Ice Concentration Retrieval With an Auxiliary Prediction Interval Estimator

    by Xinwei Chen, Ray Valencia, Armina Soleymani, K. Andrea Scott, Linlin Xu, David A. Clausi

    Bayesian neural networks (BNNs) have been demonstrated to be effective in accurate retrieval of sea ice concentration (SIC) from multi-source data, while providing estimates of uncertainty, which are essential for downstream services. However, uncertainty obtained by BNNs are intrinsically uncalibrated, which indicates that it may not correlate well with model error. To address this issue, we investigate a new approach that combines an auxiliary prediction interval (PI) estimator with the BNN-based SIC mean estimator to develop a well-calibrated SIC retrieval model that is both accurate and reliable. We adopt a training strategy called “uncertainty matching" to train the model, which ensures that the estimated uncertainties match the estimated PIs. We use a subset of AMSR2 brightness temperature data and ERA5 atmospheric data collected from 2014 to 2015 in the Baffin Bay area as input features of the model. Comparison between model inference and SIC labels obtained from the enhanced NASA Team (NT2) algorithm shows that the proposed approach is able to produce well-calibrated uncertainty with more accurate predictions in marginal ice zones.


  • Predicting Sea Ice Concentration With Uncertainty Quantification Using Passive Microwave and Reanalysis Data: A Case Study in Baffin Bay

    by Xinwei Chen, Ray Valencia, Armina Soleymani, K. Andrea Scott

    In recent years, the adoption of deep learning (DL) techniques for predicting sea ice concentration (SIC) given both passive microwave (PM) data and reanalysis data has seen a growing interest. For use in downstream services, these sea ice concentration estimates should be accompanied by uncertainty estimates. To provide these estimates, we utilize a heteroscedastic Bayesian neural network (HBNN), which can estimate both model (epistemic) and data (aleatoric) uncertainty. We use both PM and atmospheric data as our input features, and demonstrate that both are needed for accurate SIC estimates. Results show that over an annual cycle, the months of melt onset, such as April, May, and June produce the highest uncertainties relative to other months, with total (epistemic + aleatoric) uncertainties of approximately 20%, while areas in the marginal ice zone, contributed highest total uncertainty of 25% spatially. When considering an average over the test year, the level of uncertainty due to the data (aleatoric) is consistent with other studies, at 10%-15%. The advantage of our approach is that the uncertainties are specific to the data instance, and both model and data uncertainty are estimated.


  • Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)

    by Arne Scholz, Thomas Oellerich, Akhtar Hussain, Sarah Lindner, Ulrich Luecking, Annette O. Walter, Peter Ellinghaus, Ray Valencia, Franz von Nussbaum, Dominik Mumberg, et al.

    PTEFb/CDK9 mediated transcription of short-lived anti-apoptotic survival proteins like Mcl-1 and Myc, plays a critical role in cancer cell growth and survival in various tumor entities including AML. In addition, these survival proteins exhibit important functions in the development of resistance to chemotherapy. In contrast to pan-CDK inhibitors, to our knowledge PTEFb selective inhibitors have not been explored for clinical utility. We report the preclinical activity of BAY 1143572, a novel selective PTEFb/CDK9 inhibitor (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr DDT02-02) currently being investigated in Phase I clinical trials in advanced cancer (NCT01938638) and acute leukemia (NCT02345382) in various in vitro, ex vivo and in vivo models of AML. BAY 1143572 inhibited the proliferation of 7 MLL-rearrangements positive and negative AML cell lines with a median IC50 of 385 nM (range 230-1100 nM) and induced apoptosis. Furthermore, BAY 1143572 showed potent in vitro activity in 8 out of 10 non-MLL-rearranged patient derived AML samples incl. NPM1 mutant and Flt3-ITD positive samples derived from intermediate and high risk patients. Moreover, we elucidated the dynamic changes of the cellular proteome/phosphoproteome upon pharmacological and genetic PTEFb inhibition and identified PTEFb interaction partners in various AML in vitro models. These analyses uncover the oncogenic PTEFb-dependent signaling networks and substantiate the molecular rationale for the use of PTEFb inhibitors in this indication. When applied in vivo, BAY 1143572 exhibited single agent efficacy at tolerated doses in 4 out of 5 AML xenograft tumor models in mice and in 2 out of 2 AML xenograft tumor models in rats upon once daily oral administration. Of note, partial or even complete remissions could be achieved in several models. Furthermore, intermittent dosing schedules with up to 4 days treatment pauses were feasible in terms of efficacy and tolerability. Using MOLM-13 xenografts in mice and rats to address the in vivo MoA of BAY 1143572, a transient inhibition of RNA polymerase II phosphorylation, MYC mRNA and protein levels, MCL-1 mRNA and protein levels, and an induction of apoptosis was documented. In conclusion, our data provide the rationale for the initiation of clinical development of BAY 1143572 as a potent and highly selective inhibitor of PTEFb/CDK9 with first-in-class potential for the treatment of AML patients. A phase I clinical trial to determine the safety, tolerability and recommended Phase 2 dose in this indication is ongoing (NCT02345382). Citation Format: Arne Scholz, Thomas Oellerich, Akhtar Hussain, Sarah Lindner, Ulrich Luecking, Annette O. Walter, Peter Ellinghaus, Ray Valencia, Franz von Nussbaum, Dominik Mumberg, Michael Brands, Stuart Ince, Hubert Serve, Karl Ziegelbauer. BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3022.